NAD+ is the coenzyme that lets cells turn fuel into usable energy, and it declines with age in measured human samples. Here is the mechanism, the five places it shows up as tiredness, and what the human trials actually found.
Longevity
Published by Astra, which offers some of the treatments discussed. Educational, not medical advice.
The reason NAD+ is discussed at all in the context of energy is that its decline with age has been observed directly in human samples. An analysis of the plasma NAD+ metabolome across adult ages found it dysregulated in what the authors described as normal aging, meaning the shift is not a disease finding but a feature of getting older 1.
Tissue work points the same direction. A study of human tissue across the lifespan reported age-associated changes in NAD+ metabolism alongside markers of oxidative stress, with lower coenzyme levels in older tissue 2.
What this does not give you is a personal number. There is no routine clinical assay for your NAD+ status and no accepted threshold for deficiency, so the decline is a population-level observation rather than something you can test and treat like ferritin or TSH.
NAD+ is the electron acceptor that energy metabolism runs through. Glycolysis, the citric acid cycle, and oxidative phosphorylation all depend on NAD+ cycling to NADH and back. A detailed review of NAD+ metabolism during ageing sets out that dependency and adds the part that makes the pool feel small: NAD+ is also consumed as a substrate by the sirtuin and PARP enzyme families that run DNA repair and metabolic signalling 3.
So the same molecule is simultaneously the currency of energy production and the raw material of cellular maintenance. When damage-repair demand is high, it draws on the same supply energy production needs.
This is a mechanistic argument, and mechanistic arguments are the weakest kind of clinical evidence. They tell you why an intervention might work. They do not tell you whether it does.
The most directly relevant human evidence comes from a 12-week randomized, placebo-controlled trial of an oral NAD+ precursor in older adults, which reported improvement in fatigue measures relative to placebo 4. The population matters, the duration matters, and so does the fact that fatigue was self-reported.
An acute double-blind crossover trial adds a complementary result. Supplementation with an NAD+ precursor improved redox homeostasis and exercise performance in older individuals, with the same protocol not producing the same effect in young participants 6. Read together, the two trials describe an effect that appears where the deficit is, and not where it is not.
That is a modest, defensible claim, and it is worth stating what it is not. It is not evidence that NAD+ supplementation restores youthful energy, and it is not evidence that applies to a healthy 30-year-old with a sleep debt.
Fatigue reported by patients is very often cognitive rather than muscular: slower recall, a shorter attention span, an afternoon where nothing sticks. The brain has the highest metabolic demand of any tissue in the body and depends on the same NAD+ pool.
A 2022 review examined NAD+ and precursor supplementation in relation to cognitive decline across disease contexts, summarising both the mechanistic rationale and the state of human evidence 5. It is a review, which means it maps the field rather than settling it, and the field it maps is not yet settled.
The reasonable position: cognitive tiredness is a legitimate presentation of a metabolic constraint, and NAD+ is a plausible participant in it. Plausible is not proven.
Caffeine antagonises adenosine receptors. Adenosine accumulation is part of how the brain reports that you are tired, so blocking the receptor suppresses the report. Nothing about that process increases the amount of ATP your cells can produce, which is a function of metabolism running on NAD+ 3.
This explains the familiar pattern of diminishing returns. Additional caffeine adds more blockade of a signal, not more of the resource the signal was reporting on, and it frequently costs sleep quality, which is the one intervention that reliably repays the deficit.
Three separate levers, then: caffeine adjusts perception, sleep repays the debt, and cellular energy production sets the ceiling. Confusing the first for the third is the most common mistake in the entire tiredness conversation.
Start with the differential, not the supplement. Persistent tiredness has a long list of common causes worth excluding with a clinician: fragmented sleep, iron deficiency, thyroid dysfunction, sleep apnea, depression, alcohol, and medication effects. Every one of them is more likely than a coenzyme deficit and most are treatable.
Next, address the inputs with the strongest evidence base: consistent sleep timing, aerobic and resistance exercise, sufficient protein, and morning daylight. These outperform every product discussed here.
If you still want to try NAD+ support after that, treat it as a time-boxed experiment. The trials that found anything ran 12 weeks in older adults 46. Give it a comparable window and judge it honestly at the end.
The mechanism for NAD+ and energy is textbook. The clinical case is two modest trials in older adults. Both statements are true, and only one of them is usually quoted.
Astra Editorial
In older adults, two randomized trials found improvements: fatigue measures over 12 weeks with an oral precursor, and redox and exercise performance acutely, with no equivalent effect in young participants 46. That is not the same as a general energy benefit for everyone.
Almost all of the human trial evidence is for oral precursors such as nicotinamide riboside and nicotinamide mononucleotide. Injectable NAD+ has a much thinner direct human literature, so the case for it is mechanistic rather than demonstrated.
Not usefully. There is no routine clinical assay and no established reference range that would let a result guide treatment, which is why the decline is described as a population-level finding 1.
The trial that reported a fatigue benefit ran for 12 weeks 4. If you try a precursor or a prescribed program, use a comparable window before deciding whether it did anything.
Astra offers compounded NAD+ injection, prescribed by a licensed physician and dispensed by a state-licensed US compounding pharmacy, taken at home rather than as a clinic infusion. It is not FDA-approved, and the injectable-specific evidence is thinner than the oral precursor trials described above. Rule out the common causes of fatigue with a clinician first.
This guide is educational and is not medical advice. Compounded medications are not FDA-approved. Speak with a licensed physician about your own care.